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Abstract
In the U.S., deaths due to pulmonary embolism (PE) account for 9.2% of all pregnancy related 
deaths or approximately 1.5 deaths per 100,000 live births. Maternal deaths and maternal 
morbidity due to PE are more common among women who deliver by cesarean section. In the past 
decade, the clinical community has increasingly adopted venous thromboembolism (VTE) 
guidelines and thromboprophylaxis recommendations for pregnant women. Although deep vein 
thrombosis rates have decreased during this time-period, PE rates have remained relatively 
unchanged in pregnancy hospitalizations and as a cause of maternal mortality. Changes in the 
health profile of women who become pregnant, particularly due to maternal age and co-
morbidities, needs more attention to better understand the impact of VTE risk during pregnancy 
and the postpartum period.
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Introduction
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is both a morbidity during pregnancy and a cause of pregnancy-
related mortality. Pregnant women have a 4.0–4.6 higher risk of a VTE compared to 
similarly age non-pregnant women.1,2 The median absolute VTE risk during pregnancy is 
reported to be 5.7 per 10,000 deliveries, with the preponderance of studies showing an 
increased risk of VTE through each passing trimester of pregnancy, a peak one to three 
weeks postpartum and then a decline in risk equivalent to a non-pregnant state by 12 weeks 
postpartum.1–8 The increased hypercoagulable state brought on by the physiological changes 
during pregnancy is likely an evolutionary protective mechanism against hemorrhaging 
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during childbirth, but it also marks pregnancy as a strong risk factor for VTE.1,9–11 Other 
pregnancy-related VTE risk factors are decreased venous outflow in the pelvic vasculature 
due to uterine compression, decreased mobility, and vascular injury from maternal 
complications such as preeclampsia and eclampsia.5,9,11–13 Risk factors for VTE in the 
general population such as older age, black race, chronic diseases, obesity, trauma, cancer, a 
history of VTEs, thrombophilia, and recent surgery including cesarean delivery can impart 
additional risk of VTE during pregnancy and the postpartum period.3,9,11,13,14
Pregnancy-related VTE morbidities
Morbidities associated with pregnancy-related VTE such as swelling, pain, ulceration, skin 
discoloration, recurrence of a thromboses, and post-thrombotic syndrome can be acute or 
within months or years of the VTE event.15,16 The morbidities associated with VTE are 
serious and can reduce the quality of life for the affected individual.11,15 Chronic thrombotic 
pulmonary hypertension is a reported complication among 4% of PE patients up to 2 years 
after the diagnosis.17 Longterm pregnancy-related VTE morbidities come from two follow-
up studies conducted outside the U.S. In a study of 104 Swedish women surveyed 7–27 
years after the VTE event, leg ulceration was the most severe outcome among women with 
DVT during pregnancy. A study conducted in Norway demonstrated that up to 42% of 
women with pregnancy-related DVT and 24% with pregnancy-related PE developed post-
thrombotic syndrome 316 years after the initial diagnosis.
Two studies using the Nationwide Inpatient Sample (NIS), the largest database of all-payer 
U.S. inpatient hospital stays derived from billing data, showed overall increases since the 
mid-1990s in rates of recorded pregnancy-associated VTE, although stable after 2004.9,18 
From 1994–2009, VTE-associated pregnancy hospitalizations increased 14% (1.74 to 1.99 
per 1000 deliveries), and increased 17% (0.57 to 0.67 per 1000 deliveries) and 47% (0.40 to 
0.59 per 1000 deliveries) for antepartum and postpartum hospitalizations, respectively.18 
From 1998–2009, thrombotic PE recorded as a severe maternal morbidity among pregnant 
women increased approximately 72% during delivery (0.81 to 1.39 per 10,000 delivery 
hospitalizations) and 169% during postpartum hospitalizations (1.33 to 3.57 per 10,000 
delivery hospitalizations).19 Indeed these increases are alarming, though it is not clear to 
what extent the increases in VTE rates among pregnant women through the mid-2000s were 
due to a true rise in VTE or due to greater detection of PE through use of computed 
tomographic pulmonary angiography (CTPA). After the introduction of CTPA in 1998, there 
was a 2.7 fold increase in PE incidence among obstetric admissions, with little change in 
mortality based on NIS data from 1998–2006.20
VTE maternal mortality
PE has accounted for about 9–11% of U.S. pregnancy-related deaths over the past 20 years, 
and has remained among the top ten causes based on national data from the CDC Pregnancy 
Mortality Surveillance System (PMSS).21 Over the past two decades, the proportionate 
contribution of PE among other causes of pregnancy-related death has decreased (11.2 to 
9.2%), outpaced by deaths due to cardiovascular diseases.21 For this article, we pooled 
PMSS data for the period 1998–2013 and report 985 pregnancy-related PE deaths with a 
pregnancy-related death rate of 1.5 deaths per 100,000 live births due to PE. Previous reports 
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regarding maternal deaths from PE observed a calculated rate of 1.6 deaths per 100,000 live 
births (2011–2013) and a second study reporting 1.1 deaths per 100,000 deliveries (2000–
2001) using NIS data.21–23 The risk of maternal death from a PE is higher during the 
postpartum period. A study using NIS data found that from 1998–2009, PE accounted for 
8.8% of maternal deaths during postpartum hospitalizations compared to 6.7% of maternal 
deaths during delivery hospitalizations.19 Among the PE deaths in PMSS for 1998–2013, 
26% were during pregnancy and just over 60% were after delivery, the majority of which 
were within 42 days of delivery (Fig. 1).21,24,25 We also evaluated PMSS data by mode of 
delivery since past studies have demonstrated that cesarean delivery can increase the risk of 
a pregnancy-associated VTE up four-fold.9,11,26 There were 586 deaths due to PE for the 
period 1998–2013 with known modes of delivery; 69% of the women had a cesarean 
delivery and 31% had a vaginal delivery.
Current VTE trends, 2004–2014
We conducted analyses using NIS data to observe VTE, DVT, and PE prevalence rates in 
pregnancy hospitalizations during the time when VTE prevention guidelines and 
recommendations were adopted and patient safety initiatives and quality measures 
implemented. Similar methodologies were used for identifying pregnancy hospitalizations 
and for International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-
CM) coding for VTE, DVT, and PE.18,19 However, two nonspecific pregnancy codes were 
excluded from this analysis, which in turn resulted in lower rates of DVT and VTE reported 
in this review. We did not stratify on risk factors, such as race/ ethnicity due to high 
proportions of missing data. According to previous studies, PE rates among delivery 
hospitalizations had been increasing since the 90s.18,19 Here we show that after 2004, PE 
rates began to stabilize, consistent with prior analyses,18 and by 2014 the rate was 1.04 PEs 
per 10,000 delivery hospitalizations (Table 1). DVT rates showed a 16% decrease (5.3 to 4.4 
DVTs per 10,000 delivery hospitalizations) from 2004–2014, similar to decreases described 
in Ghaji et al.18
Among postpartum hospitalizations (Table 1), overall VTE rates remained unchanged from 
2004 to 2014. The trend was the primary result of a small decrease (10%) in the DVT rates 
(3.2 in 2004 to 2.9 in 2014 per 10,000 postpartum hospitalizations), as PE rates increased 
36% (1.4 to 1.9 per 10,000 postpartum hospitalizations) from 2004 to 2009 and decreased 
12% from (1.9 to 1.6 per 10,000 postpartum hospitalizations) from 2009 to 2014. DVTs 
occur three to four times more often than PEs among pregnancy-associated VTEs, and a 
high-risk period for a PE is after delivery.1,2,8,9,11 The estimated number of PE cases in 2014 
was at least one and half times more frequently associated with postpartum hospitalizations 
(n = 626) compared to delivery hospitalizations (n = 394). In contrast, the estimated number 
of DVT cases were at least one and half times higher during delivery hospitalizations (n = 
1680) compared to those associated with postpartum hospitalizations (n = 1080). The lower 
DVT rates associated with postpartum hospitalizations may be due to in part to outpatient 
treatment of the women at risk for VTE after delivery.
We also stratified by mode of delivery among delivery hospitalizations and observed 
prevalence rates of VTE, DVT, and PE. Fig. 2 shows that among cesarean deliveries from 
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2004, VTE rates decreased overall by 31%, primarily due to decreasing DVT rates. PE rates 
leveled off from 2011 to 2014 reaching 2.3 PEs per 10,000 delivery hospitalizations. We saw 
a 40% decrease in DVT rates by cesarean section (9.4 to 5.6 DVTs per 10,000 delivery 
hospitalizations). For vaginal deliveries (Fig. 3), however, we did not observe decreases in 
rates of either of VTE, DVT, or PE. Unfortunately, we could not conduct analyses by mode 
of delivery among postpartum hospitalizations because of a lack of information regarding 
mode of delivery.
Conclusion
Adoption of system-wide patient safety initiatives that adhere to VTE prevention guidelines 
and recommendations may have helped reduce DVT rates in the US and overall VTE rates 
among pregnant women from 2004–2014. Similar to other studies, we show continued 
decreases in VTE rates to 2014 among overall delivery hospitalizations.1,9,18 The decreases 
in DVT rates were greatest among women delivering by cesarean section. PE rates during 
delivery and postpartum hospitalizations as well as its relative contribution to maternal 
deaths remained unchanged. Our results among vaginal deliveries possibly reflect an 
absence of well-defined recommendations for prevention of VTE among women delivering 
vaginally except for women with prior events and/or thrombophilias.27 Today, developing 
evidence on how to provide thromboprophylaxis among women who delivery vaginally 
represents an opportunity to prevent thromboembolic events and to reduce morbidity among 
these women. Furthermore, risk factors for cardiovascular disease such as older age, obesity, 
and hypertension, the latter of which can impart complications such as preeclampsia or 
eclampsia, are also risk factors for pregnancy-associated VTE.9 These risk factors are 
increasing among pregnant women.18,21 Providers should continue to discuss with their 
patients the different morbidities that put them at greater risk of a pregnancy-associated VTE 
and opportunities to reduce their risk.
Acknowledgments
The findings and conclusions of this report are those of the authors and do not necessarily represent the official 
position of the US Centers for Disease Control and Prevention.
REFERENCES
1. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism 
during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):
697–706. [PubMed: 16287790] 
2. Pomp ER, Lenselink AM, Lenselink FR, Doggen CJ. Pregnancy, the postpartum period and 
prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 
2008;6(4):632–637. [PubMed: 18248600] 
3. Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism 
in pregnancy and puerperiuma register-based case-control study. Am J Obstet Gynecol. 
2008;198(2):233.e1–7.
4. Sultan AA, West J, Tata LJ, et al. Risk of first venous thromboembolism in and around pregnancy: a 
population-based cohort study. Br J Haematol. 2012;156(3):366–373. [PubMed: 22145820] 
5. Parunov LA, Soshitova NP, Ovanesov MV, et al. Epidemiology of venous thromboembolism (VTE) 
associated with pregnancy. Birth Defects Res C Embryo Today. 2015;105(3):167–184. [PubMed: 
26406886] 
Abe et al. Page 4
Semin Perinatol. Author manuscript; available in PMC 2020 February 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6. Brown HL, Hiett AK. Deep vein thrombosis and pulmonary embolism in pregnancy: diagnosis, 
complications, and management. Clin Obstet Gynecol. 2010;53(2):345–359. [PubMed: 20436310] 
7. Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of 
objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999;94(5 Pt 
1):730–734. [PubMed: 10546719] 
8. Blanco-Molina A, Trujillo-Santos J, Criado J, et al. Venous thromboembolism during pregnancy or 
postpartum: findings from the RIETE registry. Thromb Haemost. 2007;97(2): 186–190. [PubMed: 
17264945] 
9. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy 
and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 
2006;194(5):1311–1315. [PubMed: 16647915] 
10. Stein PD, Hull RD, Kayali F, et al. Venous thromboembolism in pregnancy: 21-year trends. Am J 
Med. 2004;117(2):121–125. [PubMed: 15234649] 
11. James AH. Thrombosis in pregnancy and maternal outcomes. Birth Defects Res C Embryo Today. 
2015;105(3):159–166. [PubMed: 26383185] 
12. James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program. 
2009:277–285. [PubMed: 20008211] 
13. Abdul Sultan A, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women 
in hospital: population based cohort study from England. BMJ. 2013;347:f6099.
14. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet 
Gynecol. 1999;94(4):595–599. [PubMed: 10511366] 
15. Bergqvist A, Bergqvist D, Lindhagen A, Matzsch T, et al. Late symptoms after pregnancy-related 
deep vein thrombosis. Br J Obstet Gynaecol. 1990;97(4):338–341. [PubMed: 2340259] 
16. Wik HS, Jacobsen AF, Jacobsen L, Sandset PM. Long-term impact of pregnancy-related venous 
thrombosis on quality of-life, general health and functioning: results of a cross-sectional, case-
control study. BMJ Open. 2012;2(6).
17. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary 
hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–2264. [PubMed: 
15163775] 
18. Ghaji N, Boulet SL, Tepper N, Hooper WC. Trends in venous thromboembolism among 
pregnancy-related hospitalizations, United States, 1994–2009. Am J Obstet Gynecol. 2013;209(5): 
433.e1–8.
19. Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and 
postpartum hospitalizations in the United States. Obstet Gynecol. 2012;120(5):1029–1036. 
[PubMed: 23090519] 
20. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: 
evidence of overdiagnosis. Arch Intern Med. 2011;171(9):831–837. [PubMed: 21555660] 
21. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United 
States, 2011–2013. Obstet Gynecol. 2017;130(2):366–373. [PubMed: 28697109] 
22. Franks AL, Atrash HK, Lawson HW, Colberg KS. Obstetrical pulmonary embolism mortality, 
United States, 1970–85. Am J Public Health. 1990;80(6):720–722. [PubMed: 2343959] 
23. https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_01.pdf.
24. Atrash HK, Ellerbrock TV, Hogue CJ, Smith JC. The need for national pregnancy mortality 
surveillance. Fam Plann Perspect. 1989;21(1):25–26. [PubMed: 2539303] 
25. Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 
19911997. Obstet Gynecol. 2003;101(2):289–296. [PubMed: 12576252] 
26. Blondon M, Casini A, Hoppe KK, et al. Risks of venous thromboembolism after cesarean sections: 
a meta-analysis. Chest. 2016;150(3):572–596. [PubMed: 27262227] 
27. Friedman AM, Ananth CV. Obstetrical venous thromboembolism: epidemiology and strategies for 
prophylaxis. Semin Perinatol. 2016;40(2):81–86. [PubMed: 26742600] 
Abe et al. Page 5
Semin Perinatol. Author manuscript; available in PMC 2020 February 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1- 
Timing of maternal deaths from pulmonary embolism, PMSS 1998–2013.
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Fig. 2- 
Rates of venous thromboembolism per 10,000 delivery hospitalizations among cesarean 
deliveries, nationwide inpatient sample, 2004–2014.
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Fig. 3- 
Rates of venous thromboembolism per 10,000 delivery hospitalizations among vaginal 
deliveries, nationwide inpatient sample, 2004–2014.
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